Core Viewpoint - Rosen Law Firm has initiated a class action lawsuit on behalf of investors of Sprouts Farmers Market, Inc. for the period between June 4, 2025, and October 29, 2025, encouraging affected investors to secure legal counsel before the deadline of January 26, 2026 [2][4]. Group 1: Class Action Details - Investors who purchased Sprouts Farmers Market securities or sold put options during the specified Class Period may be eligible for compensation without incurring out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must act by the specified deadline to serve as lead plaintiff, representing other class members in the litigation [4][8]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions, highlighting its own success in recovering significant amounts for investors [5]. - The firm has been recognized for its achievements in securities class action settlements, including a notable settlement against a Chinese company and ranking highly in the number of settlements since 2013 [5]. Group 3: Case Allegations - The lawsuit alleges that the defendants provided misleading information regarding Sprouts Farmers Market's growth potential for fiscal year 2025, claiming resilience in its customer base despite macroeconomic pressures [6]. - It is claimed that the defendants concealed material adverse facts, leading to a significant slowdown in sales growth, contrary to the positive statements made to investors [6].

Core Viewpoint - A securities class action lawsuit has been filed against aTyr Pharma, Inc. following an 83% stock collapse after the failure of its flagship drug trial, Efzofitimod, to meet its primary endpoint [1] Summary by Relevant Sections Legal Allegations - The lawsuit alleges that aTyr and its executives provided materially false and misleading information regarding the efficacy of Efzofitimod, leading to inflated stock prices [1] - The core issue revolves around whether the company accurately represented its clinical trial data and design [1] Clinical Trial Performance - The primary endpoint of the Phase 3 EFZO-FIT study was not met, specifically regarding the change from baseline in mean daily oral corticosteroid (OCS) dose [1] - Allegations include the concealment of adverse facts about the drug's ability to allow patients to taper off steroids completely, which is a key measure of efficacy [1] Market Impact - Following the announcement of the trial results, aTyr's stock price plummeted from $6.03 to $1.02, representing an 83.2% loss [1] - The lawsuit seeks to determine if investors are entitled to damages due to the alleged wrongful acts and omissions by the defendants [1] Next Steps for Investors - Hagens Berman is advising investors who purchased aTyr shares during the class period (November 7, 2024, through September 12, 2025) and suffered losses to submit their claims [1] - The deadline for investors to move for appointment as lead plaintiff is December 8, 2025 [1]

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Western Alliance Bancorporation due to allegations of materially misleading business information [1] Group 1: Legal Actions and Stock Impact - Western Alliance Bancorporation initiated a lawsuit against Cantor Group V LLC for fraud related to collateral loans, resulting in a 10.88% stock price drop on October 16, 2025 [3] Group 2: Class Action Information - Investors who purchased Western Alliance Bancorporation securities may be entitled to compensation through a class action without any out-of-pocket fees, with Rosen Law Firm preparing to seek recovery of investor losses [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [4]

Core Viewpoint - Rosen Law Firm is reminding investors of WPP plc to secure counsel before the December 8, 2025 deadline for a securities class action related to the purchase of American Depositary Shares (ADS) during the specified class period [2][3]. Group 1: Class Action Details - Investors who purchased WPP ADSs between February 27, 2025, and July 8, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and those wishing to serve as lead plaintiff must act by December 8, 2025 [4]. - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [5]. Group 2: Allegations Against WPP - The complaint alleges that WPP provided overly positive statements to investors while concealing material adverse facts about its media arm, which was reportedly not equipped to handle macroeconomic challenges and was losing market share [6].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Tandem Diabetes Care, Inc. due to allegations of materially misleading business information issued by the company [1]. Group 1: Company Information - Tandem Diabetes Care, Inc. issued a press release on August 7, 2025, announcing a voluntary medical device correction for select t:slim X2 insulin pumps, addressing a potential speaker-related issue that could lead to insulin delivery discontinuation [3]. - Following the announcement, Tandem Diabetes' stock experienced a significant decline of 19.9% on the same day [3]. Group 2: Legal Actions - Investors who purchased Tandem Diabetes Care securities may be eligible for compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses related to the misleading information [2]. Group 3: Rosen Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and being ranked No. 1 for the number of settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [4].

NEW YORK, Dec. 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of MoonLake Immunotherapeutics (NASDAQ: MLTX) between March 10, 2024 and September 29, 2025, both dates inclusive (the “Class Period”), of the important December 15, 2025 lead plaintiff deadline. SO WHAT: If you purchased MoonLake common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency ...

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of Nidec Corporation due to allegations of materially misleading business information [1] Group 1: Investigation and Allegations - Nidec Corporation is facing scrutiny after a probe into allegations of improper accounting, which led to a significant drop in its share price [3] - Following the announcement of the investigation, Nidec's American Depositary Receipts (ADRs) fell by 22.7% on September 4, 2025, marking the largest one-day drop for the company [3] Group 2: Class Action Details - Shareholders who purchased Nidec Corporation securities may be entitled to compensation through a class action lawsuit, with no out-of-pocket fees due to a contingency fee arrangement [2] - Interested investors can join the class action by submitting a form or contacting the law firm directly [2] Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest ever against a Chinese company [4] - The firm has been consistently ranked among the top firms for securities class action settlements and has recovered hundreds of millions of dollars for investors [4]

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Molina Healthcare, Inc. due to allegations of violations of federal securities laws, including making false or misleading statements regarding the company's financial health and medical cost trends [2][3]. Summary by Sections Legal Investigation - Faruqi & Faruqi, LLP is encouraging investors who suffered losses in Molina Healthcare to contact them directly to discuss legal options [1]. - The firm has set a deadline of December 2, 2025, for investors to seek the role of lead plaintiff in a federal securities class action against Molina [2]. Allegations Against Molina Healthcare - The complaint alleges that Molina and its executives failed to disclose material adverse facts about the company's medical cost trend assumptions and the dislocation between premium rates and medical costs [3]. - It is claimed that Molina's near-term growth relied on a lack of utilization of various health services, which led to a substantial likelihood of cutting financial guidance for fiscal year 2025 [3]. Financial Performance and Stock Impact - On July 7, 2025, Molina announced second-quarter financial results, revealing adjusted earnings of approximately $5.50 per share, which was below prior expectations due to medical cost pressures [3]. - The company cut its full-year 2025 adjusted earnings per share guidance by 10.2%, from at least $24.50 to a range of $21.50 to $22.50 [3]. - Following this announcement, Molina's stock price fell by $6.97, or 2.9%, closing at $232.61 per share on July 7, 2025 [3]. Further Financial Adjustments - On July 23, 2025, Molina further slashed its full-year 2025 earnings guidance, reporting a GAAP net income of $4.75 per diluted share for the second quarter, an 8% decrease year over year [4]. - The new guidance for full-year 2025 adjusted earnings was set at no less than $19.00 per diluted share, representing a 13.6% cut from the previous guidance [4]. - Molina's stock price dropped by $32.03, or 16.84%, closing at $158.22 per share on July 24, 2025, following this announcement [4].

Core Viewpoint - Rosen Law Firm is investigating potential securities claims on behalf of shareholders of America's Car-Mart, Inc. due to allegations of materially misleading business information issued to the investing public [1]. Group 1: Legal Action and Investor Rights - Shareholders who purchased America's Car-Mart securities may be entitled to compensation through a class action lawsuit without any out-of-pocket fees [2]. - The Rosen Law Firm is preparing a class action to seek recovery of investor losses [2]. Group 2: Company Performance and Market Reaction - On September 4, 2025, America's Car-Mart reported a first-quarter loss of $0.69 per share, compared to a net loss of $0.15 per share in the same period the previous year [3]. - Following the release of these results, America's Car-Mart's stock experienced a decline of 18.2% on the same day [3]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company [4]. - The firm was ranked No. 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions of dollars for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4].

Core Viewpoint - aTyr Pharma, Inc. is facing a securities class action lawsuit due to a significant stock drop of 83% following the failure of its drug trial for Efzofitimod, which did not meet its primary endpoint [1][2]. Company Overview - The lawsuit alleges that aTyr and its executives provided materially false and misleading information regarding the efficacy of Efzofitimod, leading to inflated stock prices [2]. - The firm Hagens Berman is leading the litigation and emphasizes the importance of accurate representation of clinical trial data in biotech securities cases [3]. Legal Allegations - The core issue revolves around whether aTyr misrepresented the drug's ability to help patients taper off steroid usage, a critical measure of efficacy [3][5]. - The complaint highlights a gap between the company's optimistic public statements and the actual performance of Efzofitimod in the Phase 3 EFZO-FIT study [4]. Financial Impact - Following the announcement of the trial results, aTyr's stock plummeted from $6.03 to $1.02, reflecting an 83.2% loss on September 15, 2025 [5]. - Investors who purchased shares during the class period (November 7, 2024, through September 12, 2025) and suffered losses are encouraged to submit their claims [6]. Next Steps for Investors - Hagens Berman has a history of securing over $2.9 billion in settlements for investors and is advising affected investors to act before the lead plaintiff deadline of December 8, 2025 [6].